Pamplona

• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 7 2024-11-14 Advance solid tumors
• Study of MEN1703 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Recruiting
  2024-513098-31-00 4 2024-11-14 Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
• Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers Recruiting
  2023-509767-25-00 1 2024-11-07 Advanced PRAME Positive Cancers
• Novel treatment with botulinum toxin for erectile dysfunction unresponsive to conventional treatment Recruiting
  2024-514518-10-00 4 2024-10-31 Erectile dysfunction
• Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo … Recruiting
  2024-516777-77-00 4 2024-10-31 Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GE
• Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting
  2023-505334-10-01 7 2024-10-30 Unresectable, Locally Advanced, or Metastatic Solid Tumors
• A Clinical Trial to Assess a New Anti-Cancer Treatment (called DSB2455) Given On Its Own in Patients with Advanced Malignancies Recruiting
  2023-508805-26-00 1 2024-10-23 patients with active brain metastases, where the primary tumour has co
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi … Recruiting
  2023-509851-15-00 5 2024-10-22 Colon cancer
• Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting
  2023-510429-14-00 4 2024-10-22 HER2-mutated or overexpressed/amplified solid tumours
• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO … Recruiting
  2023-508760-29-00 5 2024-10-21 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron … Recruiting
  2023-508338-33-00 5 2024-10-01 Chronic Inflammatory Demyelinating Polyneuropathy
• A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting
  2023-510136-36-00 1 2024-09-27 Advanced Non-Hodgkin’s Lymphoma
• First-in-human Trial of EGL-001 in Patients with Selected Advanced and/or Metastatic Solid Tumors Recruiting
  2024-512921-10-00 1 2024-09-27 Advanced and/or Metastatic Solid Tumors
• A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting
  2023-507803-76-00 10 2024-09-26 Peripheral T-Cell Lymphoma
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508811-21-00 10 2024-09-25 Refractory Focal Onset Epilepsy
• A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl … Recruiting
  2022-500800-24-00 4 2024-09-19 Multiple Myeloma
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer Recruiting
  2023-504013-68-00 1 2024-09-06 Advanced or Metastatic Prostate Cancer
• A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy … Recruiting
  2024-511074-80-01 7 2024-09-06 Platinum-resistant high-grade ovarian cancer (PROC) or relapsed/refrac
• Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer … Recruiting
  2023-505616-38-00 4 2024-09-04 Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (
• Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting
  2023-507692-21-00 3 2024-08-22 Antiphospholipid syndrome
• A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Recruiting
  2023-507809-34-00 9 2024-08-07 Relapsed or Refractory Systemic Light Chain Amyloidosis
• A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli … Recruiting
  2023-506199-28-00 1 2024-08-05 Dose escalation: Advanced Solid Tumors Dose Expansion: Squamous non-sm

Showing 289–312 of 829 trials